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Polyglutamine expansion in androgen receptor (AR)
is responsible for spinobulbar muscular atrophy
(SBMA) that leads to selective loss of lower motor
neurons. Using SBMA as a model, we explored the
relationship between protein structure/function and
neurodegeneration in polyglutamine diseases. We
show here that protein arginine methyltransferase 6
(PRMT6) is a specific co-activator of normal and
mutant AR and that the interaction of PRMT6 with
AR is significantly enhanced in the AR mutant. AR
and PRMT6 interaction occurs through the PRMT6
steroid receptor interaction motif, LXXLL, and the
AR activating function 2 surface. AR transactivation
requires PRMT6 catalytic activity and involves
methylation of arginine residues at Akt consensus
site motifs, which is mutually exclusive with serine
phosphorylation by Akt. The enhanced interaction
of PRMT6 and mutant AR leads to neurodegenera-
tion in cell and fly models of SBMA. These findings
demonstrate a direct role of arginine methylation in
polyglutamine disease pathogenesis.
INTRODUCTION
Polyglutamine diseases are neurodegenerative disorders
caused by expansion of CAG trinucleotide repeats encoding pol-
yglutamine tracts in specific genes (Orr and Zoghbi, 2007). The88 Neuron 85, 88–100, January 7, 2015 ª2015 The Authorsfamily of polyglutamine diseases includes spinal and bulbar
muscular atrophy (SBMA), Huntington’s disease (HD), denta-
torubral-pallidoluysian atrophy (DRPLA), and spinocerebellar
ataxia (SCA) type 1, 2, 3, 6, 7, and 17. These disorders are
caused by glutamine expansions in androgen receptor (AR),
huntingtin, atrophin-1, ataxin-1, ataxin-2, ataxin-3, CACNA1A,
ataxin-7, and the TATA-box binding protein (TBP), respectively.
One unsolved question in the field of polyglutamine diseases is
why the samemutation in different genes causes the dysfunction
and death of specific populations of neurons in the CNS, leading
to different clinical disease manifestations. The selective
pattern of neuronal degeneration in the CNS contrasts with the
widespread distribution or housekeeping function displayed by
the disease proteins. This indicates that expansion of polyglut-
amine tracts is necessary, but not sufficient to cause disease.
Evidence has been obtained that intrinsic protein features play
a critical role in dictating the initiation and progression to cellular
dysfunction and degeneration (Graham et al., 2006; Katsuno
et al., 2002; Klement et al., 1998; Tsuda et al., 2005), suggesting
a mechanistic link between expanded polyglutamine-induced
toxicity and protein structure/function (Parodi and Pennuto,
2011).
SBMA clinical and pathological features clearly illustrate the
relevance of protein context to disease pathogenesis. SBMA is
an X-linked motor neuron disease characterized by selective
degeneration of lower motor neurons (Kennedy et al., 1968). In
the family of polyglutamine diseases, SBMA is unique in that
the disease fully manifests only in males. The hormone-depen-
dent nature of SBMA is well recapitulated in animal models of
disease, including the fruit fly Drosophila melanogaster (Pandey
et al., 2007; Takeyama et al., 2002). The sex specificity of SBMA
and the toxicity of polyglutamine-expanded AR result from bind-
ing to its natural ligand, testosterone, or its more potent deri-
vative, dihydrotestosterone (DHT). Upon hormone binding, AR
translocates to the nucleus, undergoes a conformational change
that leads to amino/carboxy-terminal (N/C) interactions, binds
DNA at androgens response elements (AREs), and recruits spe-
cific transcription co-factors, including chromatin remodeling
factors, to regulate the expression of androgen-responsive
genes. Although most of these hormone-induced post-transla-
tional events have been associated with disease pathogenesis
(Katsuno et al., 2003, 2005; Lieberman et al., 2002; Montie
et al., 2009; Nedelsky et al., 2010; Orr et al., 2010), the mecha-
nism through which hormone binding converts mutant AR into
a toxic species is an important open question.
In response to hormone binding, AR acquires numerous
post-translational modifications (Pennuto et al., 2009), most
of which play a critical role in disease pathogenesis (Parodi
and Pennuto, 2011). We previously demonstrated that phos-
phorylation of polyglutamine-expanded AR by Akt at serines
215 and 792, which lie in the Akt consensus site motif RXRXXS
(where R is arginine, S serine, and X any amino acid), reduces
hormone binding and AR transactivation and protects from
neurodegeneration (Palazzolo et al., 2007; Palazzolo et al.,
2009). Similar to phosphorylation, arginine methylation is a
post-translational modification with major impact on protein
structure and function (Bedford and Clarke, 2009). Arginine
methylation is catalyzed by a family of enzymes known as pro-
tein arginine methyltransferases (PRMTs), which differ in their
activity, substrate specificity and subcellular localization.
Mammalian cells express at least 11 PRMTs. Apart from the
most recently identified PRMT10 and 11, all the other PRMTs
have catalytic activity and are classified as type I or II depend-
ing of the type of methylated arginine generated. Type I in-
cludes PRMT1, 2, 3, 4, 6, and 8 and catalyzes the addition of
two methyl groups to one of the two u-guanidino nitrogen
atoms of arginine, thereby generating asymmetric dimethylar-
ginine. Type II includes PRMT5, 7, and 9 and catalyzes the addi-
tion of one methyl group to each u-guanidino nitrogen atoms to
generate symmetric dimethylarginine. PRMTs target histones
and non-histone proteins (Di Lorenzo and Bedford, 2011; Wei
et al., 2014) and have been shown to act as co-factors of AR
and other nuclear hormone receptors (Lee et al., 2005; Meyer
et al., 2007; Sun et al., 2014). However, nothing is known as
to whether PRMTs target polyglutamine proteins and play a
role in polyglutamine disease pathogenesis.
To address this question, we used SBMA as a model of poly-
glutamine diseases. Our results show a key role for arginine
methylation in the pathogenesis of polyglutamine diseases and
provide evidence that a causative link between primary structure
and function of polyglutamine protein is the underlying mecha-
nism in the pathogenesis of polyglutamine diseases.
RESULTS
PRMT6 Is a Co-Activator of Polyglutamine-Expanded AR
To determine whether arginine methylation contributes to
polyglutamine-induced neurodegeneration, we investigated the
role of PRMT function on SBMA pathogenesis. First, we as-sessed whether eight mammalian PRMTs (PRMT1–8) colocalize
and interact with mutant AR. We analyzed the subcellular distri-
bution of the PRMTs and mutant AR in COS1 cells expressing
polyglutamine-expanded AR with 65 glutamine residues
(AR65Q) and the PRMTs tagged to enhanced GFP (EGFP).
Consistent with previous reports (Herrmann et al., 2009),
PRMT1, 3, and 4 localized predominantly to the cytosol,
PRMT2 and 7 localized to the nucleus and cytosol, PRMT6
was present almost exclusively in the nucleus, PRMT5 formed
cytosolic aggregates, and PRMT8 had plasma membrane local-
ization due to myristoylation (Figure S1A). AR localized mostly to
the cytosol in vehicle-treated cells and to the nucleus in DHT-
treated cells. AR subcellular localization and nuclear transloca-
tion in response to hormone treatment were not affected by
the overexpression of any of these PRMTs. In the DHT-treated
cells, mutant AR co-localized with PRMT2, 6, and 7 in the nu-
cleus. Similar results were obtained with non-expanded AR
(data not shown). By immunoprecipitation assay in DHT-treated
HEK293T cells co-expressing Flag-tagged AR together with
either soluble EGFP or the EGFP-tagged PRMTs, normal and
polyglutamine-expanded AR specifically formed a complex
with PRMT2, 6, and 7 (Figure 1A and Figure S1B). To test
whether the PRMTs act as transcription co-factors of AR, we
measured AR transactivation by transcriptional assay in
HEK293T cells transfected with either normal AR (AR24Q) or
AR65Q under the control of the Cytomegalovirus promoter,
and using as reporter the luciferase gene whose expression
was driven by an ARE, as previously described (Palazzolo
et al., 2007). Among the PRMTs tested here, only PRMT6 signif-
icantly increased the transcriptional activity of AR (Figure 1B).
The effect of PRMT6 was hormone dependent, indicating that
PRMT6 acts as a co-activator of AR rather than as a general
transcription activator, and it did not result from altered AR
expression (Figure S1C). Importantly, PRMT6 increased the
transactivation of AR24Q by 3.3-fold and that of AR65Q by
5.3-fold, indicating that the effect of PRMT6 on AR transactiva-
tion is enhanced by polyglutamine expansion. Similar results
were obtained by expressing non-expanded and polyglut-
amine-expanded AR under the control of an elongation factor
1 promoter (Figure S1D). These results show that PRMT6 is a
specific AR co-activator, whose function is enhanced by poly-
glutamine expansion.
Polyglutamine Expansion Enhances the Interaction of
AR with PRMT6 in Neuronal and Patient-Derived Cells
PRMT6 is expressed to a similar extent in control and SBMA
cells, including rat PC12 cells stably expressing either normal
AR with 10 glutamine residues (AR10Q) or mutant AR with 112
glutamine residues (AR112Q) (Walcott and Merry, 2002), mouse
motor neuron-derived MN-1 cells stably expressing either
AR24Q or AR65Q (Brooks et al., 1997), as well as human primary
fibroblasts and induced pluripotent stem cells (iPSCs) derived
from normal subjects and SBMA patients (Grunseich et al.,
2014) (Figure S2A). Upon hormone treatment, normal and poly-
glutamine-expanded AR colocalized with endogenous PRMT6
in the nucleus of control and SBMA PC12 cells (Figure 1C and
Figure SB). AR112Q forms intranuclear inclusions in response
to hormone binding in the PC12 cells (Walcott and Merry,Neuron 85, 88–100, January 7, 2015 ª2015 The Authors 89
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2002), and PRMT6 localized to AR-positive intranuclear inclu-
sions in these cells (Figure 1C, arrows). AR and PRMT6 co-lo-
calized in the nucleus of control and SBMA human primary
fibroblasts as well as iPSCs reprogrammed to motor neurons.
Notably, PRMT6 was expressed and co-localized with polyglut-
amine-expanded AR in the ventral horn motor neurons of spinal
cord autopsy specimens derived from an SBMA patient (Fig-
ure 1C and Figure S2B). By immunoprecipitation assays, both
normal and polyglutamine-expanded AR formed a complex
with endogenous PRMT6 in PC12 and MN-1 SBMA cells (Fig-
ure 1D and Figure S2C). Furthermore, endogenous AR and
PRMT6 formed a complex in control and SBMA human primary
fibroblast cells and iPSCs. The AR/PRMT6 interaction occurred
both in the absence and presence of hormone and was signifi-
cantly enhanced by polyglutamine expansion in the MN-1 cells.
By transcriptional assay, overexpression of PRMT6 increased
the transactivation of normal AR by 3.3-fold and that of polyglut-
amine-expanded AR by 5.7-fold in the MN-1 cells (Figure 1E).
In mouse primary cortical neurons, PRMT6 increased the trans-
activation of normal AR by 1.4-fold, but this difference was not
significant (Figure 1F). Rather, in primary neurons PRMT6 signif-
icantly increased the transactivation of polyglutamine-expanded
AR by 3.8-fold. Taken together, these results indicate that poly-
glutamine expansion enhances the structural and functional
interaction of ARwith its co-activator PRMT6 in neuronal and pa-
tient-derived cells.
Transactivation of AR by PRMT6 Requires the Catalytic
Activity and LXXLL Motif of PRMT6 and the ‘‘Activating
Function 2’’ Surface of AR
We then investigated the mechanism through which PRMT6
transactivates AR. The interaction between AR and co-regu-
lators can be inhibited by the anti-androgen 5-hydroxy-1,7-
bis(3,4-dimethoxyphenyl)-1,4,6-heptatriene-3-one (ASC-J9),
which has been shown to rescue the phenotype of a mouse
model of SBMA (Yang et al., 2007). In a transcriptional assay,
ASC-J9 significantly and dose dependently decreased the
transcriptional activity of polyglutamine-expanded and non-
expanded AR induced by PRMT6 (Figure 2A and Figure S3A).
To address whether the catalytic activity of PRMT6 is required
to transactivate AR, we performed transcriptional assays in cells
treated with the pan-PRMT inhibitor adenosine dialdehyde
(Adox). Adox reduced polyglutamine-expanded AR transactiva-
tion induced by DHT by 30%, and it completely abolished the ef-
fect of PRMT6 on AR transactivation (Figure 2B and Figure S3B).
Similar results were obtained using the PRMT inhibitor 7,7’-car-
bonylbis(azanediyl)bis(4-hydroxynaphthalene-2-sulfonic acid)Figure 1. PRMT6 Is a Co-Activator of AR whose Function Is Augmente
(A) Immunoprecipitation assay in HEK293T cells transfected with Flag-tagged AR6
24 hr). Shown is one experiment out of three. IP, immunoprecipitation; IB, immu
(B) Transcriptional assay in HEK293T cells transfected with AR24Q and AR65Q
luciferase reporter vector and treated as in (A). Graph, mean ± SEM, n = 3, *p =
(C) Immunofluorescence analysis treated as in (A). Intranuclear inclusions in PC12
and HB9 were immunostained with specific antibodies and nuclei with DAPI.
(D) Immunoprecipitation assay from cells treated as in (C). Quantification (averag
were normalized to the levels of normal AR and PRMT6 in vehicle-treated cells,
(E and F) Transcriptional assays in motor neuron-derived MN-1 cells (E) and mou
SEM, n = 3, (E) *p = 0.001; (F) *p = 0.01.(AMI-1). Because Adox and AMI-1 are not specific inhibitors of
PRMT6, we generated a PRMT6 methylation-deficient mutant
by substituting valine 86with lysine and aspartate 88with alanine
(PRMT6-V86K,D88A, Figure 2C) (Boulanger et al., 2005).
PRMT6-V86K,D88A retained its capability to bind polyglut-
amine-expanded and normal AR (Figure 2B and Figure S3B, in-
sets), but it failed to transactivate AR (Figure 2B and Figure S3B),
indicating that PRMT6 requires its catalytic activity to transacti-
vate AR.
Transcriptional regulation by steroid receptors involves the
interaction with co-factors bearing LXXLL (where L is leucine
and X is any amino acid) or FXXLF (where F is phenylalanine) mo-
tifs (Heery et al., 1997). In search for FXXLF and LXXLL motifs in
the PRMT family, we analyzed the sequence of the 11 known
PRMTs (Wolf, 2009). None of these PRMTs have the FXXLF
motif, while only PRMT6 contains the LXXLL motif 353LRVLL357
(Figure 2C and Figure S4). To establish whether the 353LRVLL357
motif of PRMT6 is necessary for AR transactivation, we
substituted leucines 356 and 357 with alanines, thereby gener-
ating PRMT6-LXXAA mutant (Heery et al., 1997). Mutation of
the LXXLL motif decreased the interaction with polyglutamine-
expanded and normal AR (Figure 2D and Figure S3C, inset)
and abolished AR transactivation (Figure 2D and Figure S3C),
indicating that the ability of PRMT6 to enhance AR transcrip-
tional activity is dependent on the integrity of the 353LRVLL357
motif.
Steroid receptor primary structure is composed of an amino-
terminal domain (NTD), a DNA-binding domain (DBD), and the
ligand-binding domain (LBD) (Figure 2C). Transactivation of ste-
roid receptors by co-factors bearing the LXXLL motif occurs
through interaction with the ‘‘activating function 2’’ (AF-2) sur-
face in the LBD, which provides a hydrophobic surface flanked
by two conserved opposing charged amino acids, lysine 720
(K720) and glutamic acid 897 (E897) (Trapman and Dubbink,
2007). To test whether the interaction between PRMT6 and AR
occurs through the AF-2 surface, we performed transcriptional
assay in cells expressing AR variants in which either K720 was
substituted with alanine (K720A) to reduce interaction with co-
factors or E897 was substituted with lysine (E897K) to disrupt
binding to co-factors (Figure 2E). As controls, we testedmutation
of alanine 574 to aspartate (A574D) to prevent DNA binding, and
mutation of glycine 21 to glutamic acid (G21E) to abolish the N/C
interactions without altering interaction with co-regulators. As
expected, the A574Dmutation did not respond to hormone stim-
ulation or to PRMT6 transactivation. The G21E mutation had no
effect on AR transactivation induced by PRMT6. The K720A mu-
tation decreased the effect of PRMT6 on AR transactivation byd by Polyglutamine Expansion in Neuronal and Patient-Derived Cells
5Q and soluble EGFP or EGFP-tagged PRMT1-8 and treated with DHT (10 nM,
noblotting; MW, molecular weight.
, EGFP, EGFP-tagged PRMTs, and the androgen-responsive element (ARE)-
0.001.
cells treated with DHT (10 mM, 48 hr) are indicated by arrowheads. AR, PRMT6,
e, n = 3–4) of AR and PRMT6 is shown at the bottom of each panel, and values
*p = 0.05.
se primary cortical neurons (F) treated with DHT (10 nM, 24 hr). Graph, mean ±
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Figure 2. AR-PRMT6 Functional Interaction
Requires PRMT6 Catalytic Activity and Is
Mediated by the LXXLL Motif of PRMT6
and the AF-2 Surface of AR
(A) Transcriptional assay in HEK293T cells trans-
fected with AR65Q together with EGFP and EGFP-
tagged PRMT6, treated with DHT (10 nM, 24 hr)
and either vehicle or ASC-J9. Graph, mean ± SEM,
n = 3, *p = 0.0003, NS, nonsignificant.
(B) Transcriptional assay in HEK293T cells trans-
fected with AR65Q and soluble EGFP, EGFP-
tagged PRMT6, or the catalytically inactive
PRMT6-V86K,D88A mutant, and treated with
vehicle, DHT, and the PRMT inhibitors Adox
(10 mM) and AMI-1 (100 mM) for 24 hr. Graph,
mean ± SEM, n = 3, *p = 0.02. Inset: immunopre-
cipitation assay in HEK293T cells transfected as
indicated. Shown is one experiment representa-
tive of four.
(C) Schematic of PRMT6 and AR functional
domains.
(D) Transcriptional assay in HEK293T cells ex-
pressing AR65Q together with EGFP, PRMT6, or
PRMT6-LXXAA mutant and treated as indicated.
Graph, mean ± SEM, n = 3, *p = 0.003; NS,
nonsignificant. Inset: immunoprecipitation assay.
(E) Transcriptional assay performed in HEK293T
cells transfected with the indicated polyglutamine-
expanded ARmutants together with soluble EGFP
or EGFP-tagged PRMT6 and treated with DHT.
Graph, mean ± SEM, n = 3, *p = 0.00001.
(F) Real-time PCR analysis of P21, VEGFR2 and
SERCA2b, and reference gene, HPRT1, in MN-1
cells stably transfected with vector expressing
either AR24Q or AR100Q and vector expressing
scramble or PRMT6 shRNAs and treatedwithDHT.
Graph, mean ± SEM, n = 4, *p = 0.001, **p = 0.01.
(G) Real-time PCR analysis in AR100Q-expressing
MN-1 cells transfected with either EGFP or
PRMT6 and treated with DHT. Graph, mean ±
SEM, n = 5, *p = 0.01.10%, whereas the E897Kmutation reduced it by 60%, indicating
that the AR-PRMT6 interaction requires an intact AF-2 surface.
Next, we sought to investigate the biological significance of
AR transactivation by PRMT6. To elucidate this aspect, we
tested whether arginine methylation alters the expression of
genes regulated by AR and PRMT6 in motor neuron-derived
MN-1 cells. We focused on genes that are known targets of
PRMT6 and AR or that have previously been implicated in
SBMA pathogenesis, including cyclin-dependent kinase inhibi-
tor 1 (p21CIP/WAF1, hereafter referred to as p21),vascular
endothelial growth factor receptor 2 (VEGFR2), and sar-
co(endo)plasmic reticulum Ca(2+) ATPase 2b (SERCA2b)
(Montague et al., 2014; Sopher et al., 2004).We generated stable
MN-1 clones expressing either AR24Q or AR100Q (Figures 5A
and 5B). By real-time PCR analysis, we found that upon DHT
treatment, p21 and VEGFR2 mRNA transcript levels were down-
regulated in mutant cells (Figure 2F). We infected the cells with
lentiviruses expressing either scramble or shRNA against
PRMT6 (Phalke et al., 2012). Expression of shRNA against
PRMT6 (#2) reduced PRMT6 expression by 40% (Figure 5A),92 Neuron 85, 88–100, January 7, 2015 ª2015 The Authorsand significantly increased the expression of p21, VEGFR2,
and SERCA2b specifically in the mutant cells (Figure 2F). On
the other hand, overexpression of PRMT6 had the opposite ef-
fect on p21 expression (Figure 2G). These results support the
idea that gene expression is altered by the interaction of poly-
glutamine-expanded AR and PRMT6.
Polyglutamine-Expanded AR Is a Substrate of PRMT6
The observation that PRMT6 catalytic activity is required to acti-
vate AR prompted us to determine whether the effect of PRMT6
occurs through direct modification of AR. In an in vitro methyl-
ation assay, incubation of polyglutamine-expanded AR with
PRMT6, but not PRMT6-V86K,D88A, in the presence of the
methyl donor [3H]S-adenosylmethionine ([3H]-SAM) increased
methylated AR by 4-fold (Figure 3A and Figure S5A). Consistent
with previous findings that PRMT6 undergoes auto-methylation
(Frankel et al., 2002), methylated PRMT6 was also increased
(Figure S5B). To determine whether full-length AR is methylated,
we immunoprecipitated Flag-tagged AR expressed with either
soluble EGFP or EGFP-tagged PRMT6 in HEK293T cells and
Figure 3. PRMT6 Methylates AR at the Akt
Consensus Site RXRXXS and GAR Motifs
(A) EGFP, PRMT6, or PRMT6-V86K,D88A tagged
to EGFP and Flag-tagged AR65Q were pulled
down from HEK293T cells and incubated together
in the presence of [3H]-SAM to perform in vitro
methylation assay. Top: fluorography. Bottom:
Coomassie brilliant blue (CBB) staining. Graph,
mean ± SEM, n = 3, *p = 0.001.
(B) Normal and mutant AR were expressed in
HEK293T cells with EGFP or EGFP-tagged
PRMT6 in the presence of DHT (10 nM, 24 hr) and
immunoprecipitated with anti-AR antibody.
Methylated arginine was detected with anti-
asymmetrically dimethylated arginine antibody
(asym). Graph, mean ± SEM, n = 4, *p = 0.035,
**p = 0.017.
(C) Dimethyl arginine was analyzed as in (B).
Graph, mean ± SEM, n = 3, *p = 0.004.
(D) Schematic of the RXR and GAR motifs present
in AR (NM_000044). Nuclear localization signal is
underlined.
(E) Mass-spectrometry (MS) analysis of AR ex-
pressed in HEK293T cells with either EGFP or
EGFP-tagged PRMT6 in the presence of DHT.
Coomassie-stained gel lanes are shown as insets,
where boxes depict the excised band analyzed.
The position of ion series indicative of unmodified
(UM), mono-methyl (MM), and di-methyl (DM)
arginine at position 629 is shown. *Methylated
residues identified by MS fragmentation data.
(F) In vitro methylation assay of peptide spanning
the Akt consensus site motif located in the AF-2
surface (WT peptide), and peptides with arginine-
to-lysine (KK peptide), serine 792-to-alanine
(S792A), or serine 792-to-aspartate (S792D) sub-
stitutions incubated with PRMT6 in the presence
of [3H]-SAM. Top: fluorography. Bottom: CBB
staining. Graph, mean ± SEM, n = 3, *p = 0.001.
(G) In vitro phosphorylation assay of WT peptide,
methylated WT peptide (Me-WT), and S792A
peptide incubated with [32P]-gATP and purified
Akt. Top: autoradiography. Bottom: CBB staining.
Graph, mean ± SEM, n = 3, *p = 0.02.analyzed samples using an antibody that specifically recognizes
asymmetrically dimethylated arginine (Figure 3B). Polyglutamine
expansion increased the methylation status of AR by 1.7-fold
compared to normal AR. Overexpression of PRMT6 did not
change arginine dimethylation of both normal and mutant AR,
suggesting that endogenous PRMT6 is sufficient to methylate
AR. On the other hand, overexpression of catalytically inactive
PRMT6 (V86K,D88A) reduced the methylation of polyglut-
amine-expanded AR by 40% (Figure 3C), probably reflecting a
dominant-negative action of mutant PRMT6 (Herrmann et al.,
2005).Neuron 85, 88–1Next, we sought to identify the arginine
residues of AR that were methylated by
PRMT6. Most PRMTs target arginine res-
idues within GAR, RXR, and RGG motifs
(Feng et al., 2013; Wada et al., 2002).
AR does not have RGG motifs, while ithas one 627GAR629 motif and the three RXR motifs 210RAR212,
616RLR618, and 787RMR789 (Figure 3D). 627GAR629 motif and
R618 are part of the nuclear localization signal (Figure 3D, under-
lined). 210RAR212 and 787RMR789 are part of the two Akt
consensus site motifs RXRXXS of AR, one located in the NTD
and the other in the AF-2 surface. By mass spectrometry anal-
ysis, R629, but not R618, wasmethylated by PRMT6 in response
to hormone treatment (Figure 3E and Figure S5C). For technical
reasons, we could not resolve the arginines at the Akt consensus
sites by mass spectrometry analysis. Because of the relevance
of these sites in SBMA pathogenesis (Palazzolo et al., 2007,00, January 7, 2015 ª2015 The Authors 93
Figure 4. PRMT6 Requires Intact Akt
Consensus Site Motifs for Full AR Transac-
tivation
(A) Western blotting analysis of AR expression
levels in HEK293T cells transfected with the indi-
cated polyglutamine-expanded arginine methyl-
ation-defective AR variants and treated with DHT
(10 nM, 24 hr). b-Tub served as loading control.
Shown is one experiment out of three.
(B) Nuclear (N) and cytoplasmic (C) fractions of
HEK293T cells transfected as indicated and
treated with vehicle or DHT were analyzed by
western blotting. b-Tub was used as loading
control.
(C) Transcriptional assay in HEK293T cells ex-
pressing either AR65Q or the argininemethylation-
defective AR65Q-R629K together with EGFP or
EGFP-tagged PRMT6 and treated with DHT.
Graph, mean ± SEM, n = 3.
(D) Transcriptional assay in HEK293T cells
expressing the indicated arginine methylation-
defective or phosphorylation-defective AR vari-
ants together with EGFP and EGFP-tagged
PRMT6 and treated with DHT. Graph, mean ±
SEM, n = 5, *p = 0.03; #p = 0.001; ##p = 0.008;
###p = 0.004; NS, nonsignificant.2009), we used an in vitro methylation assay to test whether
PRMT6methylates the arginines of the Akt consensus sitemotifs
of AR (Figure 3F and Figure S5D). Peptides spanning these Akt
consensus site motifs (WT peptides) were incubated with puri-
fied PRMT6 in the presence of [3H]-SAM. As control, we made
conservative substitutions of arginines with lysines (KK pep-
tides). We found that WT but not KK peptides were methylated
by PRMT6. Collectively, these results suggest that AR is methyl-
ated by PRMT6 at arginines 210, 212, 629, 787, and 789.
Arginine Methylation and Serine Phosphorylation at the
Akt Consensus Site Motifs of AR Are Mutually Exclusive
Similar to AR, also forkhead box O (FOXO) transcription
factors, which play a critical role in neurodegeneration (Mojsi-
lovic-Petrovic et al., 2009), are arginine-methylated at Akt
consensus site motifs (Yamagata et al., 2008). Importantly,
arginine methylation of FOXO was shown to block phosphory-
lation by Akt, but not vice versa. To investigate the potential
relationship between arginine methylation and serine phos-
phorylation at the AR Akt consensus site motifs, we performed
in vitro methylation assay using peptides in which S215 and
S792 were substituted with either phospho-defective alanine
(S215A and S792A peptides) or phospho-mimetic aspartate
(S215D and S792D peptides) (Figure 3F and Figure S5D), as
we previously described (Palazzolo et al., 2007). S215A and
S792A peptides were methylated by PRMT6, suggesting that
loss of phosphorylation does not affect methylation. On the
other hand, phospho-mimetic substitution of S215 and S79294 Neuron 85, 88–100, January 7, 2015 ª2015 The Authorsabolished methylation, suggesting that
phosphorylation prevents methylation.
To determine whether methylation
affects phosphorylation, we conductedan in vitro phosphorylation assay by incubating WT peptide
spanning the Akt consensus site within the AF2 surface and
chemically modified by arginine methylation (Me-WT peptide)
with recombinant Akt in the presence of [32P]-gATP (Figure 3G).
As negative control, we used the S792A peptide. As expected
(Palazzolo et al., 2007), S792A was not phosphorylated, indi-
cating that Akt specifically targets serine 792. Incubation of
Me-WT peptide with Akt reduced the incorporation of [32P]-
gATP by 80%. Similar results were obtained with prior incuba-
tion of WT peptide with PRMT6 and [3H]-SAM, and subsequent
incubation with Akt and [32P]-gATP (Figure S5E). Together,
these results suggest that arginine methylation of the RXRXXS
motif by PRMT6 prevents phosphorylation by Akt and vice
versa.
AR Transactivation by PRMT6 Occurs through Arginine
Methylation of RXRXXS Motifs and Is Regulated by
Phosphorylation
Major events occurring upon hormone binding are protein
stabilization, nuclear translocation, and transactivation of gene
expression (Parodi and Pennuto, 2011). To investigate the func-
tional significance of arginine methylation at the 627GAR629 and
the Akt consensus site motifs, we generated the methylation-
defective AR variants, AR65Q-R629K and AR65Q-R210K,
R212K,R787K,R789K. Loss of argininemethylation at these sites
neither altered accumulation of monomeric AR in response to
hormone binding (Figure 4A), nor reduced hormone-induced nu-
clear translocation (Figure 4B). In transcriptional assays, loss of
Figure 5. PRMT6 Exacerbates the Toxicity
of Polyglutamine-Expanded AR in Motor
Neuron-Derived MN-1 Cells and PC12 Cells
(A) XTT assay in AR24Q and AR100Q MN-1 cells
transfected with scramble shRNA or two different
shRNAs against PRMT6, and treated with vehicle
andDHT (10 mM, 48 hr). Graph, mean ± SEM, n = 3,
*p = 0.0001. Western blotting analysis and quan-
tification of PRMT6 expression levels are shown at
the bottom; loading control: calnexin (CNX);
graph, mean ± SEM, n = 3, *p = 0.01.
(B) XTT assay in AR24Q and AR100Q MN-1 cells
transfected with EGFP or wild-type and mutant
(V86K,D88A and LXXAA) PRMT6 and treated with
vehicle and DHT. Graph, mean ± SEM, n = 9, *p =
0.0001, **p = 0.0004. AR and PRMT6 expression
levels are shown at the bottom. Beta-Tubulin
(b-Tub) was used as loading control.
(C) Trypan blue assay in AR112Q PC12 cells
transfected with EGFP or PRMT6 and treated with
vehicle or DHT (50 mM, 48 hr). Graph,mean ± SEM,
n = 10, *p = 0.001. AR and PRMT6 expression
levels are shown at the bottom. Calnexin (CNX)
was used as loading control.
(D) Western blotting analysis of high molecular
weight (HMW) species and monomeric AR112Q
upon PRMT6 overexpression in PC12 cells treated
with DHT. Quantification of HMW species is
shown at the bottom. Graph, mean ± sem, n = 6,
*p = 0.03.
(E) XTT assay in AR100Q MN-1 cells transfected
with scramble or PRMT6 shRNA and treated with
DHT and vehicle or LY294002 (10 mM, 24 hr).
Graph, mean ± SEM, n = 3, *p = 0.001, **p =
0.0001.
(F) Trypan blue assay in PC12 cells transiently
transfected as indicated and treated with DHT.
Graph, mean ± SEM, n = 7–11, *p = 0.001, **p =
0.05, ***p = 0.001.methylation at R629 did not affect AR transactivation by PRMT6
(Figure 4C). On the other hand, loss of arginine methylation at
the Akt consensus site motifs reduced the transactivation of
normal AR by 34% and of mutant AR by 45%, respectively (Fig-
ure 4D). These observations indicate that PRMT6 requires
the arginine residues at the Akt consensus site motifs in order
to fully transactivate polyglutamine-expanded AR. To assess
whether PRMT6-induced AR transactivation is modulated by
phosphorylation at the Akt consensus sites, we investigated
the effect of PRMT6 transactivation on phosphorylation-defec-
tive (S215A,S792A) AR variants (Figure 4D). PRMT6 did not alter
the transactivation of phosphorylation-defective non-expanded
AR, but it enhanced that of polyglutamine-expanded AR by
2.1-fold.Neuron 85, 88–1PRMT6 Is a Modifier of
Polyglutamine-Expanded AR
Toxicity In Vitro and In Vivo
Because pharmacologic (ASC-J9) or ge-
netic (AR mutation E897K) inhibition of
the interaction between mutant AR and
its co-factors suppresses toxicity (Nedel-sky et al., 2010; Yang et al., 2007), and reduces the transactiva-
tion of AR by PRMT6, we hypothesized that AR-PRMT6
interaction is pathogenetic in SBMA. To test this hypothesis,
we undertook both a loss- and a gain-of-function approach to
target PRMT6-AR interaction. The SBMA MN-1 cells that we
generated showed reduced cell viability compared to normal
cells, although this difference was not hormone dependent (Fig-
ure 5A). Silencing endogenous PRMT6 by 30%–40% with two
different shRNAs increased cell viability by 1.5-fold in the mutant
cells. Conversely, overexpression of wild-type PRMT6 as well as
PRMT6-V86K,D88A and -LXXAA mutants decreased cell
viability by 30% in both normal and mutant cells, indicating
that the effect of PRMT6 overexpression on the survival of these
cells was independent of its ability to transactivate AR00, January 7, 2015 ª2015 The Authors 95
Figure 6. PRMT6 Is a Modifier of SBMA
Pathogenesis In Vivo
(A) Light microscopy representative images of flies
expressing AR52Q, AR12Q, and AR0Q with and
without DART8 RNAi.
(B) Scan electron microscopy representative im-
ages of SBMA flies with and without DART8 RNAi.
(C) Real-time PCR analysis of DART8 transcript
levels. Graph, mean ± SEM, n = 5, *p = 0.001.
(D) Quantification of disease severity for (A).
Graph, mean ± SEM, n = 50, *p = 0.001.
(E) Light microscopy representative images of flies
expressing phosphorylation-defective AR65Q-
S215A,S792A with and without DART8 RNAi.
(F) Quantification of disease severity for (E). Graph,
mean ± SEM, n = 21–33.(Figure 5B). Notably, in the mutant cells overexpression of wild-
type, but not mutant (V86K,D88A and LXXAA), PRMT6 reduced
cell viability by 66% in a hormone-dependent manner, indicating
that PRMT6 gain of function in mutant cells enhances the toxicity
of mutant AR in a hormone-dependent fashion. PC12 cells ex-
pressing AR112Q showed reduced cell viability when treated
with hormone (Figure 5C). Overexpression of PRMT6 decreased
cell viability by 17% and 21% in the vehicle- and DHT-treated96 Neuron 85, 88–100, January 7, 2015 ª2015 The Authorscells, respectively. In these cells, DHT
treatment also reduced cell size by
15%, which was further reduced by
PRMT6 overexpression by 14% and
27% in the absence and presence of
DHT, respectively (Figure 5C). A hallmark
of polyglutamine diseases is the accumu-
lation of mutant proteins in forms of ag-
gregates or micro-oligomers, which can
be revealed as high molecular weight
species that accumulate in the stacking
portion of polyacrylamide gels (Palazzolo
et al., 2009). Overexpressing PRMT6
significantly enhanced by 1.26-fold poly-
glutamine-expanded AR aggregation,
further supporting a toxic gain-of-func-
tion effect of PRMT6 on mutant AR (Fig-
ure 5D). Treatment of the cells with the
PI3K/Akt signaling inhibitor LY294002
for 24 hr, a condition that does not elicit
overt toxicity (Palazzolo et al., 2007),
reduced the protective effect of PRMT6
knockdown on cell viability, suggesting
that PRMT6 enhances polyglutamine-
expanded AR toxicity by counteracting
its phosphorylation by Akt (Figure 5E).
Consistent with this model, PRMT6 de-
creased neither the viability nor the size
of PC12 cells expressing the phospho-
mimetic AR variant AR100Q-S215D,
S792D (Figure 5F).
To test whether PRMT6 modifies the
SBMA phenotype in vivo, we used flymodels of SBMA. Overexpression of polyglutamine-expanded
AR (AR52Q) in the eye caused degeneration of the posterior
side ommatidia (Figures 6A and 6B) (Nedelsky et al., 2010; Pan-
dey et al., 2007). Also AR with a 12 glutamine-long tract (AR12Q)
resulted in mild neurodegeneration when overexpressed in this
system, whereas AR without a polyglutamine tract (AR0Q) was
not toxic. We crossed the SBMA flies with flies in which the
PRMT6 Drosophila ortholog, DART8, was knocked down by
31% by specific RNA interference (Figure 6C). Knocking down
endogenous DART8 itself did not cause any obvious ommatidial
degeneration in flies (Figures 6A, 6B, and 6D). However, knock-
down of DART8 suppressed polyglutamine-expanded AR-
induced neurodegeneration, without altering AR expression
(Figure S6A). Notably, DART8 knockdown also suppresses the
phenotype caused by overexpression of non-expanded AR.
Knockdown of the PRMT8 Drosophila ortholog, DART2, did not
suppress the degenerative eye phenotype in this SBMA fly
model, suggesting that the effect of DART8 knockdown is spe-
cific (Figure S6B). Consistent with the idea that silencing
PRMT6 ameliorates phenotype because it results in increased
phosphorylation at the Akt consensus site motifs, DART8 knock-
down did not modify the phenotype of flies expressing phos-
phorylation-defective AR65Q-S215A,S792A (Figures 6E and
6F). Overexpression of PRMT6 in the eye of SBMA flies did not
modify phenotype, suggesting that the endogenous fly ortholog
of PRMT6 is sufficient to cause neurodegeneration (Figures S6C
and S6D). Collectively, these results indicate that PRMT6 is a
modifier of mutant AR toxicity in vivo.
DISCUSSION
Here, we show that PRMT6 co-localizes and forms a complex
with AR and that the resulting transactivation of the receptor is
significantly enhanced by polyglutamine expansion.We had pre-
viously shown that AR is phosphorylated by Akt at the RXRXXS
motifs. Here, we report that PRMT6 methylates the AR at argi-
nine residues spanning the Akt consensus site motifs and that
arginine methylation and serine phosphorylation at these sites
are mutually exclusive. Importantly, inhibition of PRMT6 sup-
pressed the toxicity of mutant AR in vitro and in vivo, whereas
overexpression of PRMT6 enhanced toxicity. Our findings estab-
lish a key role for arginine methylation and PRMT6 in the patho-
genesis of polyglutamine diseases.
Emerging evidence in the field of polyglutamine diseases sup-
ports the idea that the toxic gain of function conferred by poly-
glutamine expansion arises from alteration of the normal, native
function(s) of the mutant protein (Orr, 2012). Although the phys-
iological function(s) of several polyglutamine proteins is not
known, there is evidence from proteins of known function that
glutamine expansions act by enhancing the normal function
of the disease protein, and finally cause neurodegeneration
(McMahon et al., 2005; Mo et al., 2010). Indeed, amplification
of protein function by overexpression of AR and ataxin-1 with
non-pathogenic repeat lengths leads to a neurodegenerative
phenotype similar to that caused by polyglutamine expansion
(Fernandez-Funez et al., 2000; Monks et al., 2007; Nedelsky
et al., 2010). Consistent with this concept, knockdown of
PRMT6 not only suppressed the toxicity of polyglutamine-
expanded AR, but it also ameliorated the phenotype of flies
overexpressing normal AR, further supporting that PRMT6 con-
tributes to toxicity by enhancing the native function of AR. More-
over, there is evidence that polyglutamine expansion leads to
amplification of interaction with native cellular partners, as
reported for a variety of polyglutamine proteins, including
ataxin-1 (Lim et al., 2008), AR (Nedelsky et al., 2010), and TBP
(Friedman et al., 2007). Expanding this idea, we here presentevidence that PRMT6 acts as a co-activator of AR whose func-
tion is enhanced by polyglutamine expansion.
In SBMA, pathogenic interactions occur through the AR co-
factor interaction surface, AF-2, and an intact AF-2 domain is
indeed required for toxicity (Nedelsky et al., 2010). We show
here that the interaction between polyglutamine-expanded AR
and PRMT6 is mediated by the AF-2 surface of AR and the ste-
roid receptor interaction motif, LXXLL, of PRMT6. Hormone
binding induces a conformational change in the LBD that leads
to generation of a hydrophobic pocket that initially binds to a hy-
drophobic helix in the NTD of AR, thereby generating intra- and
inter-molecular N/C interactions. N/C interactions occur before
and are lost upon DNA binding (van Royen et al., 2007). Subse-
quently, the hydrophobic pocket mediates binding to LXXLL
motifs in transcriptional co-factors (Heery et al., 1997). Pharma-
cologic (ASC-J9) or genetic (AR mutation E897K) intervention to
disrupt the interaction of AR with co-regulators suppresses the
toxicity of mutant AR in mouse and fly models of SBMA (Nedel-
sky et al., 2010; Yang et al., 2007). A mutation abolishing DNA
binding (A574D), which occurs before binding to co-regulators,
as well as a mutation that disrupts binding to co-regulators
(E897K) suppress the eye degenerative phenotype caused by
polyglutamine-expanded AR in flies. Substitution of K720 with
alanine (K720A), which reduces interaction with co-factors,
partially attenuated neurodegeneration. On the other hand, a
mutation of glycine 21 to glutamic acid (G21E) that abolishes
the N/C interactions without altering interaction with co-regula-
tors had no effect on toxicity. Consistent with these observa-
tions, ASC-J9 as well as mutations K720A and E897K, but not
G21E, reduced transactivation of AR by PRMT6.
Post-translational modifications are critical regulators of pro-
tein function and are modifiers of polyglutamine protein toxicity
(Pennuto et al., 2009). Methylation, together with phosphoryla-
tion, is a major post-translational modification occurring in
mammalian cells, with about 2% of cellular proteins containing
dimethylated arginine residues (Bedford and Clarke, 2009). We
have previously shown that phosphorylation of polyglutamine-
expanded AR by Akt suppresses toxicity (Palazzolo et al.,
2007, 2009). Importantly, we demonstrate here that arginine
methylation prevents phosphorylation by Akt, and vice versa,
thereby implying that arginine methylation and serine phosphor-
ylation at these sites are mutually exclusive in AR. Other poly-
glutamine proteins have RXRXXS motifs. Phosphorylation of
polyglutamine-expanded huntingtin at serine 421 by Akt has
been shown to be protective in striatal neurons (Humbert et al.,
2002), whereas phosphorylation of polyglutamine-expanded
ataxin-1 at serine 776 enhances toxicity (Emamian et al., 2003).
Our findings indicate the existence of an additional important
level of regulation of phosphorylation at the RXRXXS motif by
arginine methylation, which may also play a critical role in poly-
glutamine diseases other than SBMA.
Arginine methylation has been recently implicated in the path-
ogenesis of other neurodegenerative diseases, such as amyo-
trophic lateral sclerosis (ALS). The ALS-linked fused in sarcoma
(FUS) undergoes extensive arginine methylation, and this modi-
fication alters its subcellular localization and toxicity (Dormann
et al., 2012; Scaramuzzino et al., 2013; Tradewell et al., 2012).
Moreover, arginine methylation of spliceosomal proteins affectsNeuron 85, 88–100, January 7, 2015 ª2015 The Authors 97
Figure 7. Model of Polyglutamine-Expanded AR Methylation and
Phosphorylation
Arginine methylation of polyglutamine-expanded AR by PRMT6 at the Akt
consensus site motif RXRXXS enhances function and toxicity leading to
neurodegeneration, whereas phosphorylation by Akt prevents binding to
testosterone (T), thereby protecting neurons from degeneration.interaction with survival of motor neuron (SMN), another protein
involved inmotor neuron disease (Brahms et al., 2001). However,
the mechanism through which arginine methylation affects
neuronal survival in pathological conditions is poorly under-
stood. Given the role of the PRMTs as major modifiers of his-
tones, the interaction between AR and PRMT6 may alter histone
epigenetic marks, thereby contributing to the transcription ab-
normalities that characterize SBMA neuron and muscle cells
(Lieberman et al., 2002; Mo et al., 2010). Consistent with this
idea, we found that polyglutamine-expanded AR and PRMT6
suppress the expression of specific genes in motor neuron-
derived cells, further supporting that PRMT6 contributes to dis-
ease by altering AR function and transcription regulation. The
enhanced interaction between polyglutamine-expanded AR
and PRMT6 may also lead to sequestration of PRMT6 away
from active chromatin sites, thereby causing a loss of PRMT6
function. However, the observation that loss of PRMT6 function
in mice does not cause any overt phenotype (Neault et al., 2012),
whereas gain of PRMT6 function causes premature death (Di
Lorenzo et al., 2014), argues against this idea. Rather, this evi-
dence supports our hypothesis that a gain of functional interac-
tion between PRMT6 and its native partners/substrates, e.g.,
polyglutamine-expanded AR as shown here, is the mechanism
underlying cell dysfunction and degeneration. In conclusion,98 Neuron 85, 88–100, January 7, 2015 ª2015 The Authorswe propose a model in which polyglutamine-expanded AR is
phosphorylated by Akt, an event that blocks binding to hor-
mones, protects from toxicity, and prevents methylation
(Figure 7) (Palazzolo et al., 2007, 2009). On the other hand, the
interaction between polyglutamine-expanded AR and PRMT6
leads to argininemethylation of the ARwith enhancement of pro-
tein function and toxicity.
EXPERIMENTAL PROCEDURES
Additional details are provided in the Supplemental Information section.
Cell Cultures and Transfections
MN-1, PC12, COS1, HEK293T, mouse-, and patient-derived cells were
cultured as previously described (Basso et al., 2012; Grunseich et al., 2014;
Palazzolo et al., 2007; Walcott and Merry, 2002).
Immunocytochemistry and Microscopy
Human spinal cord slides were fixed with 4% PFA, then placed in blocking so-
lution (10% NGS, 0.3% Triton X-100 in PBS) for 45 min at room temperature.
Primary antibody staining was done at 4C overnight in PBS containing 5%
NGS and 0.1% Triton X-100, using AR and PRMT6 antibodies. Slides were
then incubated with secondary antibody and then washed before drying and
adding Vectashield/DAPI stain (Vector Lab). For AR staining in IPSC-derived
motor neurons, slides were treated with 100 mM glycine after fixation and
blocked in PBS with 3% BSA. Antibody staining was performed in PBS with
3% BSA and 0.1% Tween overnight with 0.1% Tween/PBS used for all
washes. HB9 was used at 1:200 (DSHB). Coverslips were mounted with per-
mamount (Thermo).
Western Blotting, Immunoprecipitation, Nuclear-Cytosolic
Fractionation
Cells were processed as previously described (Palazzolo et al., 2007, 2009).
For analysis of AR aggregation, cell lysates were collected in lysis buffer
(150 mM NaCl, 6 mM Na2HPO4, 4 mM NaH2PO4, 2 mM EDTA [pH8], 1% Na-
DOC, 0.5% Triton X-100, SDS 0.1%). Quantifications were done using ImageJ
1.45 software.
Transcriptional and Cytotoxicity Assays
Transcriptional assays were performed using the Dual-Luciferase assay kit
(Promega), according to manufacturers’ instructions. Cell toxicity was
measured by XTT assay in MN-1 cells and trypan blue assay in PC12 cells.
Quantitative Real-Time PCR Analysis
Total RNA was extracted with Trizol (Invitrogen). 2 mg RNA were retro-tran-
scribed using the SuperScript III First-Strand Synthesis System kit (Invitrogen).
Gene expression was measured by quantitative real-time PCR using 7900 HT
Fast Real-Time PCR System (Applied Biosystems). The level of each transcript
wasmeasuredwith the threshold cycle (Ct) method. Valueswere normalized to
the mean of the cells expressing AR24Q or AR100Q, which were assigned as
100%.
In Vitro Methylation and Kinase Assays
For in vitro methylation assays, immunoprecipitated Flag-tagged AR65Q was
incubated with immunoprecipitated EGFP, EGFP-tagged PRMT6, or PRMT6-
KLA in the presence of S-adenosyl-L-[methyl-3H] methionine (Perkin Elmer).
20 mg of indicated peptides (United Biosystem) were incubated with immuno-
precipitated EGFP or EGFP-tagged PRMT6 and S-adenosyl-L-[methyl-3H]
methionine. After washing the beads, the reaction products were analyzed
by fluorography and CBB staining. For in vitro phosphorylation assays, the
indicated peptides were incubated in phosphorylation buffer (20 mM NaF,
20 mM MOPS [pH 7.2], 25 mM beta-glycerolphosphate, 10 mM MgCl2,
25 mM ATP, 1 mM Na3VO4, 5 mM EGTA, 1 mM DTT), followed by the addition
of 50 ng recombinant Akt (Upstate) and [g-
32P] ATP (Perkin Elmer). After 30min
of incubation, samples were subjected to SDS-PAGE, transferred on PVDF
membrane. Signals were detected by autoradiography.
Drosophila Analysis
All Drosophila stocks were maintained as previously described (Nedelsky
et al., 2010; Pandey et al., 2007). The AR0Q and AR65Q-S215A,S792A
transgenic line was generated at Best Gene. The DART8 (100228) and
DART2 (26058) RNAi lines were obtained from the Vienna Drosophila
RNAi Center. Eye phenotypes were examined using a Leica M205 C stereomi-
croscope. Photographs of the eyes were taken with a Leica DFC420
digital camera. Quantification of the eye phenotypes was performed as
previously described (Pandey et al., 2007). Flies collected for scanning elec-
tron microscopy (SEM) were processed as previously described (Lanson
et al., 2011).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.neuron.2014.12.031.
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